180 related articles for article (PubMed ID: 24615730)
1. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
Thomas LN; Merrimen J; Bell DG; Rendon R; Goffin V; Too CK
Prostate; 2014 May; 74(7):732-42. PubMed ID: 24615730
[TBL] [Abstract][Full Text] [Related]
2. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
3. Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells.
Thomas LN; Morehouse TJ; Too CK
Prostate; 2012 Mar; 72(4):450-60. PubMed ID: 21688280
[TBL] [Abstract][Full Text] [Related]
4. Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
Thomas LN; Chedrawe ER; Barnes PJ; Too CKL
Breast Cancer Res Treat; 2017 Jul; 164(1):27-40. PubMed ID: 28364216
[TBL] [Abstract][Full Text] [Related]
5. Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells.
Abdelmagid SA; Too CK
Endocrinology; 2008 Oct; 149(10):4821-8. PubMed ID: 18535109
[TBL] [Abstract][Full Text] [Related]
6. Prolactin and androgen R1881 induce pro-survival carboxypeptidase-D and EDD E3 ligase in triple-negative and HER2+ breast cancer.
MacDonald TM; Thomas LN; Gupta A; Barnes PJ; Too CK
Am J Cancer Res; 2020; 10(5):1321-1343. PubMed ID: 32509382
[TBL] [Abstract][Full Text] [Related]
7. Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cells.
Koirala S; Thomas LN; Too CK
Mol Endocrinol; 2014 Mar; 28(3):331-43. PubMed ID: 24433040
[TBL] [Abstract][Full Text] [Related]
8. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
10. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
[TBL] [Abstract][Full Text] [Related]
12. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
[TBL] [Abstract][Full Text] [Related]
13. Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
Benbrahim-Tallaa L; Liu J; Webber MM; Waalkes MP
Prostate; 2007 Feb; 67(2):135-45. PubMed ID: 17075824
[TBL] [Abstract][Full Text] [Related]
14. Identification and nuclear localization of a novel prolactin and cytokine-responsive carboxypeptidase D.
Too CK; Vickaryous N; Boudreau RT; Sangster SM
Endocrinology; 2001 Mar; 142(3):1357-67. PubMed ID: 11181555
[TBL] [Abstract][Full Text] [Related]
15. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Ye D; Mendelsohn J; Fan Z
Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
Bennett NC; Hooper JD; Johnson DW; Gobe GC
Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
[TBL] [Abstract][Full Text] [Related]
17. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
18. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
19. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
Hsieh JT; Chen SC; Yu HJ; Chang HC
Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
